| Drug General Information |
| Drug ID |
D0F8UV
|
| Former ID |
DIB007187
|
| Drug Name |
Nelipepimut
|
| Synonyms |
NeuVax; E75
|
| Drug Type |
Small molecular drug
|
| Indication |
Non-hodgkin's lymphoma [ICD10:C85]
|
Phase 3 |
[1]
|
|---|
| Company |
Galena biopharma
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H22N4O2
|
| Canonical SMILES |
CC1=C(C(=NO1)C2=CC=CC=C2)C3=NC(=NC=C3)NC4CCC(CC4)O
|
| InChI |
1S/C20H22N4O2/c1-13-18(19(24-26-13)14-5-3-2-4-6-14)17-11-12-21-20(23-17)22-15-7-9-16(25)10-8-15/h2-6,11-12,15-16,25H,7-10H2,1H3,(H,21,22,23)
|
| InChIKey |
HOQWCELNTHTYAP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Receptor protein-tyrosine kinase erbB-2 |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Prostate cancer
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
EGF receptor signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
ErbB2/ErbB3 signaling events
|
|
ErbB receptor signaling network
|
|
a6b1 and a6b4 Integrin signaling
|
|
Validated targets of C-MYC transcriptional repression
|
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
|
Reactome
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Bladder Cancer
|
|
Signaling by ERBB2
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health. |
|---|
| REF 2 | The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax?? in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. |
|---|
